Emerging and Evolving Biomarkers: KRAS: Recent Findings, Laboratory Considerations, and Clinical Implications
Craig Mackinnon, MD, PhD
The University of Alabama at Birmingham
Kurtis Davies, PhD
This webinar is part 7 of the Emerging and Evolving Biomarkers Series.
CME/CMLE Credit is not available for this webinar.
KRAS plays an important role in regulating cell growth and proliferation. It is commonly mutated in cancer, and recently targeted therapy is available for patients whose tumors harbors specific KRAS variants. This presentation will describe the role of KRAS in cellular signal transduction pathways, discuss different methods for testing KRAS for genetic variants, and review the clinical implications for cancers with KRAS mutation.
- Describe the KRAS signaling pathway
- Describe molecular testing methods utilized to detected variants in the KRAS gene
- Explain the clinical significance of KRAS variants
This program has been supported through educational grant funding provided by Amgen and Loxo Oncology at Lilly (for further information concerning Lilly grant funding visit www.lillygrantoffice.com.) Supporting companies had no control over its content. No personally-identifiable information regarding you is provided to any grant supporters.
AMP is pleased to collaborate in the Immunotherapy Collaborative of Oncology Networked Communities, IC-ONC. IC-ONC is a global information network in which multidisciplinary healthcare providers, responsible for treating patients with cancer, are connected via education.
Please be sure to visit www.ic-onc.org to learn more about the collaborative and all it has to offer.
Note: Join the AMP Family for discounted access to the most current educational resources!
All sales are final. No refunds will be issued.
No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentation